PDS Biotechnology Corp
PDSB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.07
KIRA · Stoqly’s AI analyst, in plain words
- PDS Biotechnology Corp lost $34.5M in fiscal 2025.
- Free cash flow was −$27.8M in fiscal 2025, — of revenue.
Market cap
$59.3M
P/E
—
Revenue
—
Net income
−$34.5M
Free cash flow
−$27.8M
Operating margin
—
PDS Biotechnology Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$34.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What PDS Biotechnology Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- PDS Biotechnology Corp
- CIK
- 0001472091
PDS Biotechnology Corp · PDSB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$16.9M | −$40.9M | −$42.9M | −$37.6M | −$34.5M |
| Diluted EPS | −$0.66 | −$1.43 | −$1.39 | −$1.03 | −$0.74 |
| Cash | |||||
| Cash from operations | −$12.5M | −$25.7M | −$33.6M | −$35.0M | −$27.8M |
| Capital expenditure | — | — | $0.0M | $0.0M | $0.0M |
| Free cash flow | — | — | −$33.6M | −$35.1M | −$27.8M |
| Share count change | 52.9% | 11.7% | 8.2% | 17.8% | 27.2% |
| Debt and strength | |||||
| Cash and short-term investments | $65.2M | $73.8M | $56.6M | $41.7M | $26.7M |
| Shareholders' equity | $63.2M | $44.0M | $26.1M | $19.0M | $9.3M |
| Current ratio | 17.8x | 7.8x | 4.3x | 2.6x | 3.0x |
| Interest coverage | — | −31.7x | −10.2x | −7.8x | −5.9x |
| Returns and quality | |||||
| Return on equity | −37.5% | −76.2% | −122.5% | −166.7% | −244.2% |
| Return on tangible equity | −26.8% | −92.8% | −164.3% | −197.9% | −372.9% |
| Altman Z'' | 17.7 | −0.9 | −7.0 | −13.7 | −25.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PDS Biotechnology Corp · PDSB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.07 a share, the company is worth $59.3M.
Source: SEC EDGAR XBRL filings (CIK 0001472091). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.